Clinical Trial Update: A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

This Phase 2 study is evaluating the bioequivalence of two subcutaneous formulations of ocrelizumab in people with multiple sclerosis; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis | Phase 2 | Status: RECRUITING